Melanocortin receptor pharmacology and sexual behaviour in preclinical models

PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist derived from Melanotan II, developed for the study of central sexual arousal pathways. Unlike PDE5 inhibitors (sildenafil) that act peripherally on smooth muscle, PT-141 acts centrally via MC3R and MC4R receptors in the hypothalamus and limbic system to modulate dopaminergic reward circuits associated with sexual motivation and arousal. It has completed Phase II and III clinical trials and received FDA approval (Vyleesi) for hypoactive sexual desire disorder in premenopausal women, providing an unusually robust clinical dataset to complement preclinical research.

Mechanism

PT-141 is a cyclic heptapeptide that selectively binds MC3R and MC4R in the central nervous system. MC4R activation in the medial hypothalamus and nucleus accumbens drives dopamine release in the mesolimbic pathway, modulating sexual motivation and erection/lubrication response in a CNS-dependent manner. Unlike MC1R (skin pigmentation) agonism associated with Melanotan II, PT-141's selectivity profile avoids significant pigmentation effects at therapeutic doses.

Plain-language summary

PT-141, known clinically as Bremelanotide and sold as Vyleesi®, is the only FDA-approved peptide specifically for sexual dysfunction — approved in 2019 for hypoactive sexual desire disorder in premenopausal women. What makes PT-141 unique is where it acts: not in the blood vessels, like Viagra or Cialis, but in the brain. It activates melanocortin receptors in the hypothalamus — a region involved in desire, arousal, and motivation — producing an increase in sexual interest that is centrally driven rather than mechanically facilitated. This makes it relevant for addressing the desire and psychological components of sexual dysfunction, which PDE5 inhibitors cannot reach. It has been studied in both men and women, giving it one of the broadest clinical research bases of any peptide on this site.

Research protocols

Protocol	Peptides	Duration	Dosage	Endpoint
Melanocortin Receptor Binding Assay	PT-141	Acute (in vitro / ex vivo)	0.1 nM – 1 µM (in vitro) · Single concentration-response curve	Ki/EC50 at MC1R, MC3R, MC4R (radioligand competition binding); cAMP accumulation (HTRF assay); β-arrestin recruitment (BRET assay)
Sexual Behaviour Model (Rodent)	PT-141	Acute to 7-day	0.1–3 mg/kg (rat); 0.3–10 mg/kg (mouse) · Single SC dose per session	Intromission latency, mount frequency, lordosis quotient (female rats), erection latency (male rats), dopamine microdialysis in nucleus accumbens

Key studies

2004

PT-141: a melanocortin agonist for the treatment of sexual dysfunction

PT-141 induced penile erection in conscious rats via central MC3R/MC4R activation, without cardiovascular effects associated with PDE5 inhibitors, confirming its central (vs. peripheral) mechanism of action.

PMID 14738977

2019

Bremelanotide (PT-141) in premenopausal women with hypoactive sexual desire disorder

Bremelanotide 1.75 mg SC significantly increased satisfying sexual events and reduced distress associated with low sexual desire vs. placebo in a Phase III randomised controlled trial.

PMID 30900992

Verdict

✓Pros

Only FDA-approved peptide drug specifically for sexual dysfunction — most complete human safety and efficacy dataset of any peptide on this site
Central mechanism (brain-driven desire) vs. peripheral mechanism (blood flow) — targets a different and complementary pathway to PDE5 inhibitors
Studied in both men and women — unusually broad clinical applicability
Relatively fast onset: peak plasma concentration in 45–60 minutes, with effects reported within 1–2 hours
Available as a pre-filled autoinjector (Vyleesi®) in the USA — demonstrates commercial viability
Phase III placebo-controlled trial data available in public literature

×Cons

Nausea is the most common side effect — reported in approximately 40% of participants in Phase III trials, sometimes severe enough to require a separate anti-nausea medication
Flushing and hyperpigmentation (temporary skin darkening) reported at higher doses
Blood pressure can temporarily increase — contraindicated in cardiovascular disease
EU vendor availability is very limited — most list PT-141 as out of stock or not carried
Subcutaneous injection required — no oral form with established efficacy
Not approved by EMA; EU self-researchers face significant sourcing barriers

Legal status

PT-141 (Bremelanotide) is an FDA-approved drug in the USA (Vyleesi®) but is not approved by the EMA in the EU. As a research compound, it is unscheduled in most EU countries but sourcing from EU vendors is very limited. Import may be subject to customs inspection. The approved clinical product is not available without a US prescription.

FAQ

How does PT-141 differ from Melanotan II?

Melanotan II is a non-selective melanocortin agonist that activates all five MCR subtypes, including MC1R (tanning) and MC2R (cortisol). PT-141 is a structural analogue engineered for greater MC3R/MC4R selectivity, reducing pigmentation side-effects and the potent nausea associated with Melanotan II at comparable doses.

Is PT-141 approved as a drug?

Yes. Bremelanotide (PT-141) was FDA-approved in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not approved by the EMA and EU availability for research purposes is limited.